Clinical trials: Alzheimer Disease; Prodromal
Alzheimer's Disease
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand [18F] Genentech Tau Probe 1 (GTP1) in the brain of participants with…
- Trial name
- NCT02640092
- Testing
- [18F]GTP1
- Where
- 16 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment.
- Trial name
- NCT06402838
- Testing
- RO7269162
- Where
- 46 sites in Chile, Denmark and 7 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease.
- Trial name
- NCT03289143
- Testing
- Semorinemab, [18F]GTP1
- Where
- 133 sites in United States, Australia and 11 more
- Volunteers
- 457 people
- Sponsor
- Genentech, Inc.
Alzheimer Disease (AD)
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
- Trial name
- NCT04566003
- Testing
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Alzheimer Disease
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03443973
- Testing
- Gantenerumab
- Where
- 155 sites in United States, Argentina and 17 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-FUTURE (NCT04846426)
- Where
- 4 sites in United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
TRC-PAD Program: In-Clinic Trial-Ready Cohort
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
- Trial name
- TRC-PAD (NCT04004767)
- Where
- 45 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Prodromal Alzheimer's Disease, Alzheimer Disease
COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study
A 2-arm (sequence), 2-period, 2-treatments, single blinded (outcome assessor), randomized crossover-trial (12+12 weeks with immediate contrast) comparing a low-carbohydrate-high-fat diet (LCHF) with a high-carbohydrate-low-fat…
- Conditions
- Prodromal Alzheimer's Disease, Alzheimer Disease, Mild Cognitive Impairment, Neurocognitive Disorders
- Trial name
- NCT06105320
- Testing
- LCHF, HCLF
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital